Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109377&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Outset Medical, Inc.(OM) should contact Levi & Korsinsky about pending Class Action - OM

NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Outset Medical securities between September 15, 2020, and August 7, 2024, inclusive (the "Class Period").

OM Stockholders Have Opportunity to Lead Outset Medical, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Outset Medical investors who were adversely affected by alleged securities fraud between September 15, 2020 and August 7, 2024.

Levi & Korsinsky Notifies Shareholders of Outset Medical, Inc.(OM) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109336&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – OM

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109264&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Outset Medical, Inc. (OM) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK , Oct. 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Period") of the important October 28, 2024 lead plaintiff deadline. So What: If you purchased Outset Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

OM Deadline: OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109250&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Outset Medical, Inc. (OM) - October 28, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109234&wire=1 or contact Joseph E. Levi, Esq.

October 28, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against OM

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.

OM FINAL DEADLINE: RLF, A GLOBAL AND LEADING LAW FIRM, Encourages Outset Medical, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – OM

LOS ANGELES, CA / ACCESSWIRE / October 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Outset Medical Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=109141&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of Outset Medical, Inc. (OM) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Outset Medical securities between September 15, 2020, and August 7, 2024, inclusive (the "Class Period").

OM Shareholders Have Opportunity to Lead Outset Medical, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=108990&wire=1 or contact Joseph E. Levi, Esq.

Outset Medical, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OM

LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

The Schall Law Firm Encourages Investors To Join A Securities Fraud Case Against Outset Medical, Inc.

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=108954&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Outset Medical, Inc.(OM) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

LOS ANGELES , Oct. 21, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Outset Medical securities between August 1, 2022, and August 7, 2024, inclusive (the "Class Period").

OM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Outset Medical, Inc. (NASDAQ:OM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/outset-medical-lawsuit-submission-form?prid=108876&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Outset Medical, Inc.(OM) should contact Levi & Korsinsky about pending Class Action - OM

LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Outset Medical Inc Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset Medical" or "the Company") (NASDAQ:OM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Outset Medical securities between August 1, 2022, and August 7, 2024, inclusive (the "Class Period").

OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Oct. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.

OM DEADLINE: RLF, A TOP-RANKED LAW FIRM, Encourages Outset Medical, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – OM

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Outset Medical, Inc.

BOSTON--(BUSINESS WIRE)-- #classaction--Berman Tabacco announces that it has filed a securities class action complaint in the United States District Court for the Northern District of California against Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) and certain current and former officers. This new securities class action is related to a pending case against Outset in the Northern District of California captioned Porcelli v. Outset Medical, Inc., et al., Case No. 24-CV-6124. The new class actio.

Berman Tabacco Announces that it has Filed a New Class Action Complaint Against Outset Medical, Inc. with an Expanded Class Period

LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Outset Medical Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

OM Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESSWIRE / October 17, 2024 / Outset Medical, Inc. (NASDAQ:OM) is facing a perilous situation as it grapples with a potential delisting from the Nasdaq and a class-action lawsuit alleging investor fraud. In a notice received on September 23, 2024, the company was informed that its common stock price had fallen below $1.00 per share for 30 consecutive trading days, violating Nasdaq's minimum bid price requirement.

News for Outset Medical Stock (OM)